Hans Peter Grimm
Overview
Explore the profile of Hans Peter Grimm including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
254
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Grimm H, Schumacher V, Schafer M, Imhof-Jung S, Freskgard P, Brady K, et al.
MAbs
. 2023 Oct;
15(1):2261509.
PMID: 37823690
There are few treatments that slow neurodegeneration in Alzheimer's disease (AD), and while therapeutic antibodies are being investigated in clinical trials for AD treatment, their access to the central nervous...
2.
Mazer N, Hofmann C, Lott D, Gieschke R, Klein G, Boess F, et al.
Alzheimers Dement
. 2022 Dec;
19(6):2287-2297.
PMID: 36454709
Introduction: A quantitative model of Alzheimer's disease (AD) based on the amyloid/tau/neurodegeneration biomarker framework (Q-ATN model) was developed to sequentially link amyloid positron emission tomography (PET), tau PET, medial temporal...
3.
Franssen L, Swat M, Kierzek A, Rose R, van der Graaf P, Grimm H
CPT Pharmacometrics Syst Pharmacol
. 2022 Nov;
12(2):139-143.
PMID: 36418887
Immunogenicity against therapeutic proteins frequently causes attrition owing to its potential impact on pharmacokinetics, pharmacodynamics, efficacy, and safety. Predicting immunogenicity is complex because of its multifactorial drivers, including compound properties,...
4.
Aldea R, Grimm H, Gieschke R, Hofmann C, Lott D, Bullain S, et al.
Alzheimers Dement (N Y)
. 2022 Jun;
8(1):e12306.
PMID: 35676943
Introduction: Amyloid-related imaging abnormalities with edema/effusion (ARIA-E) are commonly observed with anti-amyloid therapies in Alzheimer's disease. We developed a semi-mechanistic, in silico model to understand the time course of ARIA-E...
5.
Bordeau B, Polli J, Schweser F, Grimm H, Richter W, Balthasar J
Int J Mol Sci
. 2022 Jan;
23(2).
PMID: 35054865
The prediction of monoclonal antibody (mAb) disposition within solid tumors for individual patients is difficult due to inter-patient variability in tumor physiology. Improved a priori prediction of mAb pharmacokinetics in...
6.
Eigenmann M, Karlsen T, Wagner M, Tenstad O, Weinzierl T, Fauti T, et al.
Pharmaceutics
. 2021 Dec;
13(12).
PMID: 34959386
The goal of this study is to investigate the pharmacokinetics in plasma and tumour interstitial fluid of two T-cell bispecifics (TCBs) with different binding affinities to the tumour target and...
7.
Galluppi G, Brar S, Caro L, Chen Y, Frey N, Grimm H, et al.
Clin Pharmacol Ther
. 2021 May;
110(5):1172-1175.
PMID: 33991429
No abstract available.
8.
Grimm H, Schick E, Hainzl D, Justies N, Yu L, Klein C, et al.
J Pharm Sci
. 2019 Jul;
108(11):3729-3736.
PMID: 31351865
The pharmacokinetics (PK) of the anti-CD20 monoclonal antibody obinutuzumab was assessed after single intravenous dosing to cynomolgus monkeys. In addition, the pharmacokinetic-pharmacodynamic (PKPD) relationship for B-cell depletion was characterized. The...
9.
Richter W, Christianson G, Frances N, Grimm H, Proetzel G, Roopenian D
MAbs
. 2018 Apr;
10(5):803-813.
PMID: 29621428
The neonatal Fc receptor (FcRn) has been demonstrated to contribute to a high bioavailability of monoclonal antibodies (mAbs). In this study, we explored the cellular sites of FcRn-mediated protection after...
10.
Ribba B, Boetsch C, Nayak T, Grimm H, Charo J, Evers S, et al.
Clin Cancer Res
. 2018 Feb;
24(14):3325-3333.
PMID: 29463551
Optimal dosing is critical for immunocytokine-based cancer immunotherapy to maximize efficacy and minimize toxicity. Cergutuzumab amunaleukin (CEA-IL2v) is a novel CEA-targeted immunocytokine. We set out to develop a mathematical model...